JP2015528295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528295A5 JP2015528295A5 JP2015530089A JP2015530089A JP2015528295A5 JP 2015528295 A5 JP2015528295 A5 JP 2015528295A5 JP 2015530089 A JP2015530089 A JP 2015530089A JP 2015530089 A JP2015530089 A JP 2015530089A JP 2015528295 A5 JP2015528295 A5 JP 2015528295A5
- Authority
- JP
- Japan
- Prior art keywords
- ntrk1
- gene fusion
- mprip
- mprip gene
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 230000004927 fusion Effects 0.000 claims description 55
- 238000003556 assay Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 239000000523 sample Substances 0.000 claims description 20
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 18
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 17
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 15
- 208000037841 lung tumor Diseases 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 238000009104 chemotherapy regimen Methods 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 229940043355 kinase inhibitor Drugs 0.000 claims description 11
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 9
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 9
- 101150111783 NTRK1 gene Proteins 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 101150003655 Mprip gene Proteins 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 230000009286 beneficial effect Effects 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 claims 2
- WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229950003970 larotrectinib Drugs 0.000 claims 2
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 claims 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229940126496 utatrectinib Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101001028827 Homo sapiens Myosin phosphatase Rho-interacting protein Proteins 0.000 claims 1
- 102100037183 Myosin phosphatase Rho-interacting protein Human genes 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000009969 flowable effect Effects 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696002P | 2012-08-31 | 2012-08-31 | |
| US61/696,002 | 2012-08-31 | ||
| US201361827514P | 2013-05-24 | 2013-05-24 | |
| US61/827,514 | 2013-05-24 | ||
| PCT/US2013/057495 WO2014036387A2 (en) | 2012-08-31 | 2013-08-30 | Methods for diagnosis and treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528295A JP2015528295A (ja) | 2015-09-28 |
| JP2015528295A5 true JP2015528295A5 (https=) | 2017-09-07 |
| JP6223451B2 JP6223451B2 (ja) | 2017-11-01 |
Family
ID=50184648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530089A Expired - Fee Related JP6223451B2 (ja) | 2012-08-31 | 2013-08-30 | がんの診断及び治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150218652A1 (https=) |
| EP (1) | EP2890815B1 (https=) |
| JP (1) | JP6223451B2 (https=) |
| CA (1) | CA2882759C (https=) |
| WO (1) | WO2014036387A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP2914621B1 (en) * | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| CA3150658A1 (en) | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| WO2015184443A1 (en) * | 2014-05-30 | 2015-12-03 | The Regents Of The University Of Colorado | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
| CN113354649B (zh) | 2014-11-16 | 2024-12-10 | 阵列生物制药公司 | 一种新的晶型 |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| FI3439662T3 (fi) | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| CA3108236A1 (en) * | 2018-08-07 | 2020-02-13 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| CN109988836B (zh) * | 2019-03-18 | 2022-06-07 | 厦门艾德生物技术研究中心有限公司 | 一种检测ntrk融合的fish探针组及其应用 |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| EP4114967A4 (en) * | 2020-02-28 | 2025-01-29 | Advanced Cell Diagnostics, Inc. | METHODS FOR DETECTING NTRK GENE FUSION USING RNA IN SITU HYBRIDIZATION |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122655B2 (en) * | 2002-11-15 | 2006-10-17 | New England Medical Center Hospital, Inc. | Compositions involving M-RIP, and related methods for screening for anti-hypertensive agents, and uses thereof |
| PT2450437T (pt) * | 2006-04-14 | 2017-08-25 | Cell Signaling Technology Inc | Defeitos de genes e cinase alk mutante em tumores sólidos humanos |
| CA2663286A1 (en) * | 2006-09-15 | 2008-03-20 | The Governors Of The University Of Alberta | Automatedfishanalysis,circulating microfluidic chip, and method for immobilizing cells to a microfluidic chip |
| AU2009253675A1 (en) * | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| AU2010248782B2 (en) * | 2009-05-15 | 2015-06-11 | Insight Genetics, Inc. | Methods and compositions relating to fusions of ALK for diagnosing and treating cancer |
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2013059740A1 (en) * | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP2914621B1 (en) * | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
-
2013
- 2013-08-30 EP EP13832208.6A patent/EP2890815B1/en not_active Not-in-force
- 2013-08-30 WO PCT/US2013/057495 patent/WO2014036387A2/en not_active Ceased
- 2013-08-30 CA CA2882759A patent/CA2882759C/en not_active Expired - Fee Related
- 2013-08-30 US US14/423,867 patent/US20150218652A1/en not_active Abandoned
- 2013-08-30 JP JP2015530089A patent/JP6223451B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528295A5 (https=) | ||
| CA2882759C (en) | Detection of the ntrk1-mprip gene fusion for cancer diagnosis | |
| US20170114415A1 (en) | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy | |
| JP2010259438A5 (https=) | ||
| DK2329259T3 (en) | MARKERS AND PROCEDURES FOR ASSESSING AND TREATING ULCERATIVE COLITIS AND RELATED DISEASES USING A 20-GEN PANEL | |
| JP2014533949A5 (https=) | ||
| CN107022637B (zh) | 一种与重度抑郁症相关的基因标志物 | |
| KR101604178B1 (ko) | 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 | |
| CN110129442A (zh) | 甲状腺癌的分子诊治标志物 | |
| KR20220039065A (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
| CN116694764A (zh) | 一种增强人卵巢癌顺铂耐药性的piRNA标志物及其在检测和治疗中的应用 | |
| CN107630085B (zh) | 分子标志物在男性骨质疏松中的应用 | |
| CN108410978A (zh) | 重度抑郁症相关基因及其在诊断中的应用 | |
| KR101670135B1 (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| CN116397020B (zh) | 生物标志物在预测磺酸类烷化剂诱导骨髓损伤敏感性中的应用 | |
| US10895574B2 (en) | Left-right gene expression signature for triple negative breast cancer | |
| CN108034707B (zh) | Spag7基因在制备老年痴呆诊断制剂中的应用 | |
| EP4332242A1 (en) | Method for predicting prognosis of gastric cancer | |
| KR101644682B1 (ko) | 전사체학과 단백질체학을 이용한 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 | |
| CN113403382B (zh) | Ube2f在诊治股骨头坏死中的应用 | |
| KR20160043419A (ko) | 간암 바이오마커로서의 ＥＲＲγ 및 이의 용도 | |
| WO2007053659A2 (en) | Method of screening for hepatocellular carcinoma | |
| CN115058512A (zh) | 铁死亡相关基因在鉴定缺血性脑卒中的应用 | |
| KR20150081632A (ko) | 약물에 의한 간 손상 유형을 조기에 진단하기 위한 정보를 제공하는 방법 | |
| KR20210120474A (ko) | 대장암 환자에서 세툭시맙에 대한 내성 예측용 바이오마커 조성물 |